Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03131453




Registration number
NCT03131453
Ethics application status
Date submitted
5/04/2017
Date registered
27/04/2017
Date last updated
5/08/2021

Titles & IDs
Public title
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Scientific title
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).
Secondary ID [1] 0 0
2016-002976-28
Secondary ID [2] 0 0
CCNP520A2202J
Universal Trial Number (UTN)
Trial acronym
GS2
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimers Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CNP520 50mg
Treatment: Drugs - CNP520 15mg
Other interventions - Matching placebo

Experimental: CNP520 50 mg - 50 mg capsule taken orally once daily

Experimental: CNP520 15 mg - 15 mg capsule taken orally once daily

Placebo Comparator: Placebo - Matching placebo to 15 and 50 mg CNP520 taken orally once daily


Treatment: Drugs: CNP520 50mg
50 mg capsule

Treatment: Drugs: CNP520 15mg
15 mg capsule

Other interventions: Matching placebo
Matching placebo for 15 and 50 mg capsules
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Event (Diagnosis of Mild Cognitive Impairment or Dementia, Due to Alzheimer's Disease (AD))
Timepoint [1] 0 0
Baseline to last cognitive assessment performed (up to day 648)
Primary outcome [2] 0 0
Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
Timepoint [2] 0 0
Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [1] 0 0
Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Score
Timepoint [1] 0 0
Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [2] 0 0
Change in the Total and Index Scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Timepoint [2] 0 0
Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [3] 0 0
Change in the Everyday Cognition Scale (ECog-Subject) Total Scores
Timepoint [3] 0 0
Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [4] 0 0
Change in the Everyday Cognition Scale (ECog-Informant) Total Scores
Timepoint [4] 0 0
Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [5] 0 0
Number of Participants With Newly Occurring Safety MRI Abnormalities (ARIA-E, ARIA-H,White Matter Disease and Any Other MRI Abnormalities)
Timepoint [5] 0 0
Baseline up to study termination approximately 617 days
Secondary outcome [6] 0 0
Annualized Percent Change on Volume of Brain Regions
Timepoint [6] 0 0
Baseline to Week 26, Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [7] 0 0
Change in CSF Levels of Amyloid Beta 40 (Aß40)
Timepoint [7] 0 0
Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [8] 0 0
Change in CSF Levels of Amyloid Beta 42 (Aß42)
Timepoint [8] 0 0
Baseline to Last on-treatment (Day 547) and Baseline to Last off-treatment (Day 648)
Secondary outcome [9] 0 0
Change in Neurofibrillary Tangle Burden as Measured by Standardized Uptake Ratio (SUVR) of PET Scans With Tau Radiotracer (Where Available)
Timepoint [9] 0 0
Baseline to Months 24 and 60
Secondary outcome [10] 0 0
Change in Amyloid Deposition as Measured by Standardized Uptake Ratio (SUVR) of Positron Emission Tomography (PET) Scan With Amyloid Radiotracer
Timepoint [10] 0 0
Baseline to Months 24 and 60
Secondary outcome [11] 0 0
Change in CSF Levels of Total Tau and Phosphorylated Tau
Timepoint [11] 0 0
Baseline to Last on-treatment (Day 547) Baseline to Last off-treatment (Day 648)
Secondary outcome [12] 0 0
Change in Serum Neurofilaments
Timepoint [12] 0 0
Baseline to Week 26, baseline to Last on-treatment (Day 547) Baseline to Last off-treatment (Day 648)
Secondary outcome [13] 0 0
Number of Suicidal Ideation or Behavior Events
Timepoint [13] 0 0
Baseline up to study termination approximately 617 days

Eligibility
Key inclusion criteria
- consent to receive disclosure of their risk estimates to develop clinical symptoms of
AD based on their APOE genotype and, if Heterozygotes, evidence of elevated brain
amyloid.

- Male or female, age 60 to 75 years inclusive. Females must be considered
post-menopausal and not of child bearing potential

- Cognitively unimpaired as evaluated by memory tests performed at screening.

- Participant's willingness to have a study partner.

- Carrier of at least one APOE4 gene if Heterozygotes, elevated brain amyloid (as
measured by CSF Abeta or amyloid PET imaging).
Minimum age
60 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Any disability that could have prevented the participants from completing all study
requirements. -

- Current medical or neurological condition that could have impacted cognition or
performance on cognitive assessments.

- Advanced, severe progressive or unstable disease that could have interfered with the
safety, tolerability and study assessments, or put the participant at special risk.

- History of malignancy of any organ system, treated or untreated, within the past 60
months.

- Indication for, or current treatment with ChEIs and/or another AD treatment (e.g.
memantine).

- Contraindication or intolerance to MRI.

- Brain MRI results showing findings unrelated to AD that, in the opinion of the
Investigator might be a leading cause to future cognitive decline, could have posed a
risk to the participant, or could have prevented a satisfactory MRI assessment for
safety monitoring.

- Suicidal Ideation in the past six months, or Suicidal Behavior in the past two years.

- A positive drug screen at Screening, if, in the Investigator's opinion, was is due to
drug abuse.

- Significantly abnormal laboratory results at Screening, not as a result of a temporary
condition.

- Current clinically significant ECG findings.

- Clinically relevant depigmenting or hypopigmenting conditions (e.g. albinism,
vitiligo) or active / history of chronic urticaria in the past year.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/08/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/03/2020
Sample size
Target
Accrual to date
Final
1145
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Novartis Investigative Site - Darlinghurst
Recruitment hospital [2] 0 0
Novartis Investigative Site - Heidelberg West
Recruitment hospital [3] 0 0
Novartis Investigative Site - Nedlands
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Hawaii
Country [9] 0 0
United States of America
State/province [9] 0 0
Idaho
Country [10] 0 0
United States of America
State/province [10] 0 0
Illinois
Country [11] 0 0
United States of America
State/province [11] 0 0
Indiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Kentucky
Country [14] 0 0
United States of America
State/province [14] 0 0
Maine
Country [15] 0 0
United States of America
State/province [15] 0 0
Massachusetts
Country [16] 0 0
United States of America
State/province [16] 0 0
Michigan
Country [17] 0 0
United States of America
State/province [17] 0 0
Minnesota
Country [18] 0 0
United States of America
State/province [18] 0 0
Mississippi
Country [19] 0 0
United States of America
State/province [19] 0 0
Missouri
Country [20] 0 0
United States of America
State/province [20] 0 0
Nebraska
Country [21] 0 0
United States of America
State/province [21] 0 0
New Jersey
Country [22] 0 0
United States of America
State/province [22] 0 0
New Mexico
Country [23] 0 0
United States of America
State/province [23] 0 0
New York
Country [24] 0 0
United States of America
State/province [24] 0 0
North Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
Ohio
Country [26] 0 0
United States of America
State/province [26] 0 0
Oklahoma
Country [27] 0 0
United States of America
State/province [27] 0 0
Oregon
Country [28] 0 0
United States of America
State/province [28] 0 0
Pennsylvania
Country [29] 0 0
United States of America
State/province [29] 0 0
Rhode Island
Country [30] 0 0
United States of America
State/province [30] 0 0
South Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
Tennessee
Country [32] 0 0
United States of America
State/province [32] 0 0
Texas
Country [33] 0 0
United States of America
State/province [33] 0 0
Vermont
Country [34] 0 0
United States of America
State/province [34] 0 0
Washington
Country [35] 0 0
United States of America
State/province [35] 0 0
Wisconsin
Country [36] 0 0
Argentina
State/province [36] 0 0
Buenos Aires
Country [37] 0 0
Belgium
State/province [37] 0 0
Gent
Country [38] 0 0
Belgium
State/province [38] 0 0
Leuven
Country [39] 0 0
Canada
State/province [39] 0 0
British Columbia
Country [40] 0 0
Canada
State/province [40] 0 0
Nova Scota
Country [41] 0 0
Canada
State/province [41] 0 0
Nova Scotia
Country [42] 0 0
Canada
State/province [42] 0 0
Ontario
Country [43] 0 0
Canada
State/province [43] 0 0
Quebec
Country [44] 0 0
Chile
State/province [44] 0 0
Santiago
Country [45] 0 0
China
State/province [45] 0 0
Shanghai
Country [46] 0 0
China
State/province [46] 0 0
Beijing
Country [47] 0 0
China
State/province [47] 0 0
Guangdong
Country [48] 0 0
Finland
State/province [48] 0 0
Kuopio
Country [49] 0 0
Finland
State/province [49] 0 0
Turku
Country [50] 0 0
France
State/province [50] 0 0
Cedex
Country [51] 0 0
France
State/province [51] 0 0
Lille Cedex
Country [52] 0 0
France
State/province [52] 0 0
PARIS Cedex 13
Country [53] 0 0
France
State/province [53] 0 0
Rouen
Country [54] 0 0
France
State/province [54] 0 0
Toulouse Cedex 9
Country [55] 0 0
France
State/province [55] 0 0
Villeurbanne
Country [56] 0 0
Germany
State/province [56] 0 0
Bayreuth
Country [57] 0 0
Germany
State/province [57] 0 0
Berlin
Country [58] 0 0
Germany
State/province [58] 0 0
Koeln
Country [59] 0 0
Germany
State/province [59] 0 0
Leipzig
Country [60] 0 0
Germany
State/province [60] 0 0
Mannheim
Country [61] 0 0
Germany
State/province [61] 0 0
Siegen
Country [62] 0 0
Iceland
State/province [62] 0 0
Kopavogi
Country [63] 0 0
Israel
State/province [63] 0 0
Ashkelon
Country [64] 0 0
Israel
State/province [64] 0 0
Haifa
Country [65] 0 0
Israel
State/province [65] 0 0
Petach Tikva
Country [66] 0 0
Israel
State/province [66] 0 0
Ramat Gan
Country [67] 0 0
Israel
State/province [67] 0 0
Tel Aviv
Country [68] 0 0
Italy
State/province [68] 0 0
BS
Country [69] 0 0
Italy
State/province [69] 0 0
Lazio
Country [70] 0 0
Italy
State/province [70] 0 0
MB
Country [71] 0 0
Italy
State/province [71] 0 0
Milan
Country [72] 0 0
Japan
State/province [72] 0 0
Ehime
Country [73] 0 0
Japan
State/province [73] 0 0
Fukuoka
Country [74] 0 0
Japan
State/province [74] 0 0
Kanagawa
Country [75] 0 0
Japan
State/province [75] 0 0
Osaka
Country [76] 0 0
Japan
State/province [76] 0 0
Tokyo
Country [77] 0 0
Japan
State/province [77] 0 0
Chiba
Country [78] 0 0
Korea, Republic of
State/province [78] 0 0
Gyeonggi Do
Country [79] 0 0
Korea, Republic of
State/province [79] 0 0
Busan
Country [80] 0 0
Korea, Republic of
State/province [80] 0 0
Incheon
Country [81] 0 0
Korea, Republic of
State/province [81] 0 0
Seoul
Country [82] 0 0
Mexico
State/province [82] 0 0
Mexico CP
Country [83] 0 0
Mexico
State/province [83] 0 0
Nuevo Leon
Country [84] 0 0
Mexico
State/province [84] 0 0
Sinaloa
Country [85] 0 0
Netherlands
State/province [85] 0 0
Noord Brabant
Country [86] 0 0
Netherlands
State/province [86] 0 0
Amsterdam
Country [87] 0 0
Portugal
State/province [87] 0 0
Lisbon
Country [88] 0 0
Portugal
State/province [88] 0 0
Coimbra
Country [89] 0 0
Portugal
State/province [89] 0 0
Lisboa
Country [90] 0 0
Portugal
State/province [90] 0 0
Matosinhos
Country [91] 0 0
Puerto Rico
State/province [91] 0 0
San Juan
Country [92] 0 0
Singapore
State/province [92] 0 0
Singapore
Country [93] 0 0
South Africa
State/province [93] 0 0
Johannesburg
Country [94] 0 0
South Africa
State/province [94] 0 0
Western Cape
Country [95] 0 0
South Africa
State/province [95] 0 0
ZAF
Country [96] 0 0
Spain
State/province [96] 0 0
Barcelona
Country [97] 0 0
Spain
State/province [97] 0 0
Madrid
Country [98] 0 0
Spain
State/province [98] 0 0
Donostia-San Sebastian
Country [99] 0 0
Switzerland
State/province [99] 0 0
CH
Country [100] 0 0
Switzerland
State/province [100] 0 0
Geneve
Country [101] 0 0
Switzerland
State/province [101] 0 0
Lausanne
Country [102] 0 0
Taiwan
State/province [102] 0 0
Kaoshiung
Country [103] 0 0
Taiwan
State/province [103] 0 0
New Taipei City
Country [104] 0 0
Taiwan
State/province [104] 0 0
Taipei
Country [105] 0 0
United Kingdom
State/province [105] 0 0
Devon
Country [106] 0 0
United Kingdom
State/province [106] 0 0
GBR
Country [107] 0 0
United Kingdom
State/province [107] 0 0
Surrey
Country [108] 0 0
United Kingdom
State/province [108] 0 0
Avon
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Birmingham
Country [110] 0 0
United Kingdom
State/province [110] 0 0
Bristol
Country [111] 0 0
United Kingdom
State/province [111] 0 0
Dundee
Country [112] 0 0
United Kingdom
State/province [112] 0 0
Glasgow
Country [113] 0 0
United Kingdom
State/province [113] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Novartis Pharmaceuticals
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Amgen
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Banner Alzheimer's Institute
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical
status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for
the onset of clinical symptoms of AD based on their age, APOE genotype and elevated amyloid.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03131453
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03131453